Drugs with SPC(s)
1. List of Acular Ls drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
| US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(11 months from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or reducing ocular pain and burning/stinging; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating ocular pain; A method of treating or preventin...
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACULAR LS family patents
16
United States
2
Canada
2
European Union
2. List of Afinitor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 3 months ago) | |
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 3 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of patients with tuberou...
Dosage: TABLET;ORAL
AFINITOR family patents
14
Norway
14
Japan
12
European Union
10
United States
10
Israel
9
Lithuania
8
Spain
8
Russia
7
Hong Kong
7
China
7
Portugal
6
Denmark
6
Cyprus
6
Slovenia
5
Czech Republic
5
Poland
5
Slovakia
3
Canada
3
Korea, Republic of
3
Mexico
3
Luxembourg
2
United Kingdom
2
Taiwan
1
Brazil
1
New Zealand
1
Australia
1
South Africa
1
Hungary
3. List of Afinitor Disperz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 3 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 10, 2025 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 29 August, 2012
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive tr...
Dosage: TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ family patents
14
Norway
14
Japan
12
European Union
10
United States
10
Israel
9
Lithuania
8
Spain
8
Russia
7
Hong Kong
7
China
7
Portugal
6
Denmark
6
Cyprus
6
Slovenia
5
Czech Republic
5
Poland
5
Slovakia
3
Canada
3
Korea, Republic of
3
Mexico
3
Luxembourg
2
United Kingdom
2
Taiwan
1
Brazil
1
New Zealand
1
Australia
1
South Africa
1
Hungary
4. List of Amzeeq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(7 years from now) | |
| US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
| US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
AMZEEQ family patents
52
United States
5
IB
5
Canada
2
Israel
2
Australia
1
China
1
Brazil
1
South Africa
1
Mexico
1
United Kingdom
1
European Union
5. List of Aplenzin drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
| US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
APLENZIN family patents
24
United States
8
European Union
4
Canada
3
Russia
3
China
3
Japan
3
Korea, Republic of
3
Australia
3
South Africa
2
Nicaragua
2
New Zealand
2
Mexico
2
Costa Rica
2
Ecuador
2
Colombia
1
Hong Kong
1
Ireland
1
Singapore
1
Israel
6. List of Aptiom drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(6 years from now) | |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: NA
Dosage: TABLET;ORAL
APTIOM family patents
6
United States
4
Japan
3
Korea, Republic of
3
Portugal
2
Spain
2
European Union
1
Denmark
1
RS
1
Poland
1
Russia
1
China
1
Brazil
1
Canada
1
Ukraine
1
Argentina
1
Croatia
1
Cyprus
1
Mexico
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
7. List of Auvelity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10780064 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10925842 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10940124 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(11 years from now) | |
| US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10966942 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
| US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11497721 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11510918 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
198
United States
15
China
12
Australia
11
Korea, Republic of
10
Japan
9
Canada
9
European Union
8
Singapore
8
New Zealand
8
Israel
3
Brazil
3
Peru
3
Mexico
3
Costa Rica
3
Ecuador
2
Malaysia
2
Chile
2
Colombia
1
Spain
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Morocco
1
Nicaragua
1
Croatia
1
Portugal
1
Lithuania
1
Slovenia
1
Hungary
8. List of Belbuca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(9 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM;BUCCAL
BELBUCA family patents
7
United States
4
Korea, Republic of
4
Australia
3
Singapore
2
New Zealand
2
China
2
EA
1
Hong Kong
1
Brazil
1
South Africa
1
Canada
1
Ukraine
1
Israel
1
India
1
Mexico
1
Japan
1
European Union
9. List of Bromsite drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778999 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Aug, 2029
(6 years from now) | |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 08 April, 2016
Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
BROMSITE family patents
2
United States
1
Spain
1
Canada
1
Portugal
1
Denmark
1
European Union
10. List of Cabometyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS INC | c-Met modulators and methods of use |
Aug, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(1 year, 3 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
| New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma
Dosage: TABLET;ORAL
CABOMETYX family patents
20
United States
13
Japan
9
European Union
7
Australia
6
Spain
5
Hong Kong
4
Croatia
4
Denmark
4
Slovenia
3
Poland
3
Austria
2
Cyprus
2
Canada
2
Portugal
1
Luxembourg
1
Netherlands
1
Hungary
11. List of Caplyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(5 years from now) | |
| US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(5 years from now) | |
| US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(6 years from now) | |
| US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
| New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 2023-12-21
Market Authorisation Date: 20 December, 2019
Treatment: Treatment of bipolar depression; Treatment of schizophrenia
Dosage: CAPSULE;ORAL
CAPLYTA family patents
24
United States
11
Korea, Republic of
9
Japan
7
Australia
4
China
4
European Union
3
Mexico
2
Canada
1
Spain
1
Hong Kong
1
India
1
Denmark
12. List of Cometriq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(3 years from now) | |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 29 November, 2012
Treatment: NA
Dosage: CAPSULE;ORAL
COMETRIQ family patents
20
United States
13
Japan
9
European Union
7
Australia
6
Spain
5
Hong Kong
4
Croatia
4
Denmark
4
Slovenia
3
Poland
3
Austria
2
Cyprus
2
Canada
2
Portugal
1
Luxembourg
1
Netherlands
1
Hungary
13. List of Copiktra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 2022-09-24
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
COPIKTRA family patents
25
United States
8
New Zealand
7
European Union
6
China
6
Singapore
5
Russia
5
Ukraine
5
Japan
5
Mexico
4
Malaysia
4
Korea, Republic of
4
Israel
3
Philippines
3
Brazil
3
Canada
3
Australia
3
South Africa
2
Spain
2
Hong Kong
2
Denmark
1
India
1
Poland
1
Croatia
1
San Marino
1
Cyprus
1
Portugal
1
Netherlands
1
Lithuania
1
Slovenia
1
Hungary
14. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(3 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
4
Japan
2
Spain
2
Cyprus
2
Portugal
2
Denmark
2
European Union
1
United States
1
China
1
Canada
15. List of Drospirenone drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET, CHEWABLE;ORAL
DROSPIRENONE family patents
19
United States
5
European Union
4
Korea, Republic of
4
Lithuania
4
Hungary
3
Canada
3
Guatemala
3
Mexico
3
Ecuador
2
Spain
2
Denmark
2
RS
2
Poland
2
Brazil
2
Croatia
2
Peru
2
Portugal
2
Slovenia
1
Argentina
1
EA
1
Norway
1
Japan
1
New Zealand
1
Cyprus
1
Chile
1
Australia
1
South Africa
1
Colombia
16. List of Duzallo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(5 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(6 years from now) | |
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(5 years from now) | |
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(6 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET;ORAL
DUZALLO family patents
25
United States
6
China
6
Japan
5
European Union
4
EA
4
New Zealand
4
Korea, Republic of
4
Australia
4
South Africa
3
Hong Kong
3
Brazil
3
Canada
3
Taiwan
3
Mexico
2
Argentina
2
ME
2
Chile
2
Israel
1
Spain
1
Malaysia
1
Denmark
1
RS
1
Poland
1
Ukraine
1
Morocco
1
Singapore
1
Norway
1
Croatia
1
Cyprus
1
Portugal
1
Ecuador
1
Colombia
1
Lithuania
1
Luxembourg
1
Tunisia
1
Slovenia
1
Hungary
17. List of Ezallor Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10413543 | SUN PHARM | Stable multiparticulate pharmaceutical composition of rosuvastatin |
Feb, 2036
(12 years from now) | |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 18 December, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
EZALLOR SPRINKLE family patents
3
United States
2
India
1
European Union
18. List of Fleqsuvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446246 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(14 years from now) | |
| US11324696 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(14 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
Dosage: SUSPENSION;ORAL
FLEQSUVY family patents
11
United States
1
China
1
Canada
1
European Union
19. List of Galafold drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(3 years from now) | |
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
GALAFOLD family patents
12
United States
5
Japan
5
European Union
3
Spain
3
Hong Kong
2
Poland
2
Slovenia
2
Cyprus
2
Mexico
2
Denmark
2
Hungary
1
Netherlands
1
Canada
1
Portugal
1
Lithuania
1
Luxembourg
1
Australia
20. List of Givlaari drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(2 years from now) | |
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(7 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 2023-11-21
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
GIVLAARI family patents
119
United States
28
Australia
19
European Union
12
Canada
7
Japan
1
Germany
1
Austria
21. List of Gocovri drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867791 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US8741343 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US11197835 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9877933 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867793 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867792 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time with...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
GOCOVRI family patents
26
United States
4
Japan
2
China
2
Canada
2
Mexico
2
Australia
2
European Union
1
Brazil
22. List of Kazano drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
KAZANO family patents
11
United States
8
China
3
Japan
2
Argentina
2
Norway
2
Korea, Republic of
2
Israel
2
Taiwan
1
Spain
1
Hong Kong
1
Austria
1
Malaysia
1
Denmark
1
RS
1
Germany
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
New Zealand
1
Croatia
1
Cyprus
1
Portugal
1
Georgia
1
Mexico
1
Australia
1
Costa Rica
1
Netherlands
1
South Africa
1
Luxembourg
1
Slovenia
1
Hungary
1
European Union
23. List of Kloxxado drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
KLOXXADO family patents
13
United States
3
Japan
2
Canada
2
European Union
1
China
1
Morocco
1
Australia
24. List of Leqvio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(7 months from now) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(5 months from now) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(5 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 2025-12-22
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
LEQVIO family patents
639
United States
124
European Union
106
Australia
74
Japan
62
Canada
13
United Kingdom
11
Austria
10
Mexico
9
Germany
6
Spain
6
Denmark
4
China
3
Hong Kong
3
Korea, Republic of
3
Portugal
2
Russia
2
Brazil
2
Norway
2
Cyprus
2
Slovenia
1
IB
1
New Zealand
1
Indonesia
1
Hungary
25. List of Linzess drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(7 months from now) | |
| US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(3 years from now) | |
| US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(7 months from now) | |
| US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(7 months from now) | |
| US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(7 months from now) | |
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE;ORAL
LINZESS family patents
15
United States
5
Japan
5
European Union
4
China
4
Russia
3
Spain
3
Denmark
3
Brazil
3
Singapore
3
Norway
3
New Zealand
3
Korea, Republic of
3
Cyprus
3
Portugal
3
Australia
3
South Africa
3
Slovenia
2
Austria
2
Germany
2
Canada
2
Mexico
2
Luxembourg
1
Hong Kong
1
Israel
1
Netherlands
1
Lithuania
1
Hungary
26. List of Livmarli drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497745 | MIRUM | NA |
Feb, 2040
(16 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
| Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
| New Patient Population (NPP) | Mar 13, 2026 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 2025-09-29
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
LIVMARLI family patents
13
United States
3
Korea, Republic of
3
China
3
Israel
3
Canada
3
Brazil
3
Japan
3
Australia
3
European Union
27. List of Lorbrena drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
| Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
| New Indication (I) | Mar 3, 2024 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 2022-11-02
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
LORBRENA family patents
4
United States
2
Japan
2
Lithuania
2
Hungary
1
Uruguay
1
IB
1
Spain
1
Hong Kong
1
Dominican Republic
1
Philippines
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Singapore
1
Argentina
1
EA
1
Norway
1
ME
1
Nicaragua
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Cyprus
1
Peru
1
Israel
1
Chile
1
Portugal
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Cuba
1
Costa Rica
1
Netherlands
1
South Africa
1
Colombia
1
Luxembourg
1
Tunisia
1
Slovenia
1
European Union
28. List of Mekinist drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
| New Product (NP) | Mar 16, 2026 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an...
Dosage: SOLUTION;ORAL
MEKINIST family patents
9
United States
6
Japan
3
European Union
2
Spain
2
Denmark
2
RS
2
Poland
2
China
2
Canada
2
Norway
2
Croatia
2
Cyprus
2
Portugal
2
Slovenia
1
Austria
1
Hong Kong
1
Germany
1
Russia
1
Brazil
1
ME
1
New Zealand
1
Korea, Republic of
1
Mexico
1
Australia
1
Netherlands
1
South Africa
1
Luxembourg
1
Hungary
29. List of Mitosol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9539241 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jan, 2028
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8186511 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(3 years from now) | |
| US9205075 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(3 years from now) | |
| US7806265 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Feb, 2029
(5 years from now) | |
| US9649428 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
May, 2029
(5 years from now) | |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery
Dosage: FOR SOLUTION;TOPICAL
MITOSOL family patents
6
United States
2
Japan
2
European Union
1
Canada
1
Australia
30. List of Nesina drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | |||